MedTrace Logo

Cognitive Impairment and Affective Mood Disorders in Patients With IBD

NCT05760729 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2023-03-08

No results posted yet for this study

Summary

The aim is to evaluate the presence of mild cognitive impairment (MCI) in patients with inflammatory bowel disease (IBD). This will be done by cognitive tests. Along them, screening for depression, anxiety and stress will be done. A blood sample for determining serum values of homocysteine, protein S100-B, amyloid and BDNF will be stored. Patients will be followed-up for 2 years.

Conditions

Interventions

DIAGNOSTIC_TEST

Cognitive testing

Cognitive tests will be carried: MOCA, trail making test, digit symbol substitution, forward and backward digit testing.

Sponsors & Collaborators

  • Iuliu Hatieganu University of Medicine and Pharmacy

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2025-05-30
Completion
2025-05-30

Countries

  • Romania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05760729 on ClinicalTrials.gov